Entry Point Capital, LLC Castle Biosciences Inc Transaction History
Entry Point Capital, LLC
- $221 Million
- Q4 2024
A detailed history of Entry Point Capital, LLC transactions in Castle Biosciences Inc stock. As of the latest transaction made, Entry Point Capital, LLC holds 29,144 shares of CSTL stock, worth $736,760. This represents 0.35% of its overall portfolio holdings.
Number of Shares
29,144
Previous 9,282
213.98%
Holding current value
$736,760
Previous $264,000
193.94%
% of portfolio
0.35%
Previous 0.15%
Shares
2 transactions
Others Institutions Holding CSTL
# of Institutions
210Shares Held
26.6MCall Options Held
128KPut Options Held
35.4K-
Black Rock Inc. New York, NY3.04MShares$77 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.83MShares$46.3 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT1.8MShares$45.4 Million0.24% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.44MShares$36.3 Million0.02% of portfolio
-
Dimensional Fund Advisors LP Austin, TX999KShares$25.3 Million0.01% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $665M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...